Validation of the IPF-specific version of St. George's Respiratory Questionnaire
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Validation of the IPF-specific version of St. George's Respiratory Questionnaire. / Prior, Thomas Skovhus; Hoyer, Nils; Shaker, Saher Burhan; Davidsen, Jesper Rømhild; Yorke, Janelle; Hilberg, Ole; Bendstrup, Elisabeth.
I: Respiratory research, Bind 20, 199, 08.2019.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Validation of the IPF-specific version of St. George's Respiratory Questionnaire
AU - Prior, Thomas Skovhus
AU - Hoyer, Nils
AU - Shaker, Saher Burhan
AU - Davidsen, Jesper Rømhild
AU - Yorke, Janelle
AU - Hilberg, Ole
AU - Bendstrup, Elisabeth
PY - 2019/8
Y1 - 2019/8
N2 - Background: Patients with idiopathic pulmonary fibrosis (IPF) have impaired health-related quality of life (HRQL). To measure HRQL, an IPF-specific version of the St. George's Respiratory Questionnaire (SGRQ-I) was developed, but not sufficiently validated. This study aimed to assess the validity (i.a. known-groups validity and concurrent validity) and test-retest reliability of SGRQ-I in IPF patients with different disease durations. Methods: Patients with IPF were consecutively recruited and completed SGRQ, SGRQ-I, King's Brief Interstitial Lung Disease questionnaire (K-BILD), University of California, San Diego Shortness of Breath Questionnaire (SOBQ) and Short Form-36 (SF-36) along with pulmonary function tests and a 6-min walk test (6MWT) at baseline. After two weeks, SGRQ-I and Global Rating of Change Scales (GRCS) were completed. Results: At baseline and after two weeks, 150 and 134 patients completed the questionnaires, respectively. The internal consistency of SGRQ-I was high (Cronbach's α = 0.92). Good concurrent validity was demonstrated by high intraclass correlation coefficients (ICC = 0.97), Bland-Altman plots and moderate to strong correlations to K-BILD, SOBQ and SF-36 (r = - 0.46 to 0.80). High ICC (0.92) and a Bland-Altman plot indicated good test-retest reliability. SGRQ-I was good at discriminating between patients with different stages of disease (Δscore > 18.1, effect sizes > 0.10). Validity was similar across groups of different disease duration. Conclusions: SGRQ-I proved to be valid at distinguishing between different disease severities, valid compared to other HRQL instruments, applicable across different disease durations and reliable upon repetition. SGRQ-I is a valid option for measuring HRQL in patients with IPF. Trial registration: The study was registered at clinicaltrials.org (NCT02818712) on 15 June 2016.
AB - Background: Patients with idiopathic pulmonary fibrosis (IPF) have impaired health-related quality of life (HRQL). To measure HRQL, an IPF-specific version of the St. George's Respiratory Questionnaire (SGRQ-I) was developed, but not sufficiently validated. This study aimed to assess the validity (i.a. known-groups validity and concurrent validity) and test-retest reliability of SGRQ-I in IPF patients with different disease durations. Methods: Patients with IPF were consecutively recruited and completed SGRQ, SGRQ-I, King's Brief Interstitial Lung Disease questionnaire (K-BILD), University of California, San Diego Shortness of Breath Questionnaire (SOBQ) and Short Form-36 (SF-36) along with pulmonary function tests and a 6-min walk test (6MWT) at baseline. After two weeks, SGRQ-I and Global Rating of Change Scales (GRCS) were completed. Results: At baseline and after two weeks, 150 and 134 patients completed the questionnaires, respectively. The internal consistency of SGRQ-I was high (Cronbach's α = 0.92). Good concurrent validity was demonstrated by high intraclass correlation coefficients (ICC = 0.97), Bland-Altman plots and moderate to strong correlations to K-BILD, SOBQ and SF-36 (r = - 0.46 to 0.80). High ICC (0.92) and a Bland-Altman plot indicated good test-retest reliability. SGRQ-I was good at discriminating between patients with different stages of disease (Δscore > 18.1, effect sizes > 0.10). Validity was similar across groups of different disease duration. Conclusions: SGRQ-I proved to be valid at distinguishing between different disease severities, valid compared to other HRQL instruments, applicable across different disease durations and reliable upon repetition. SGRQ-I is a valid option for measuring HRQL in patients with IPF. Trial registration: The study was registered at clinicaltrials.org (NCT02818712) on 15 June 2016.
KW - Health-related quality of life
KW - Idiopathic pulmonary fibrosis
KW - Interstitial lung disease
KW - IPF-specific version of the St. George's respiratory questionnaire
KW - K-BILD
KW - Quality of life
KW - SGRQ
KW - SGRQ-I
U2 - 10.1186/s12931-019-1169-9
DO - 10.1186/s12931-019-1169-9
M3 - Journal article
C2 - 31462235
AN - SCOPUS:85071622006
VL - 20
JO - Respiratory Research (Print)
JF - Respiratory Research (Print)
SN - 1465-9921
M1 - 199
ER -
ID: 241356021